Whether you realize it or not, biotech blue-chip stock Amgen (NASDAQ:AMGN) has had a stellar year. You may not see that reflected in its share price considering the magnitude of the recent stock market correction, but over the past year Amgen has witnessed five of its 10 key late-stage therapies receive approval from the Food and Drug Administration.
Hey, check out all the research scientist jobs. Post your resume today!
